IJRAR.ORG E-ISSN: 2348-1269, P-ISSN: 2349-5138

INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS (IJRAR) | IJRAR.ORG

An International Open Access, Peer-reviewed, Refereed Journal

A Review and Update on Diuretics

AVNEESH RAJPUT[1], DR MAYANK THAKUR[2]

1 Research Scholar, Department of Pharmacology, Advance Institute of Biotech & Paramedical Sciences, Kanpur, Uttar Pradesh, India, 2 Associate Professor, Advance Institute of Biotech & Paramedical Sciences, Kanpur, Uttar Pradesh, India.

Abstract

Diuretics are recommended as first-line treatment for hypertension and may also help with hypervolemia and electrolyte imbalances. This article highlights the essential characteristics the most often prescribed diuretics. Following that, we provide an update on recent clinical trials including diuretics. Thiazide diuretics are more effective than b-blockers and angiotensin-converting enzyme inhibitors in preventing stroke and are at least as effective as other kinds of medications in minimising cardiovascular events (CVEs) in hypertensive individuals. When compared to the frequently used thiazide, hydrochlorothiazide, Chlorthalidone lowers CVEs by one-fifth, as shown by observational cohort data and a network analysis. When compared to, chlorthalidone increases life expectancy a placebo. In comparison to placebo, the diuretic indapamide decreases CVEs in people aged 80 and above. Eplerenone, an aldosterone antagonist, reduces overall mortality in patients with early congestive heart failure. Following an acute myocardial infarction (MI), the benefit of eplerenone is restricted to dosing 3 to 6 days after the MI. It has been shown that aldosterone antagonists reduce the risk of proteinuria and sudden cardiac mortality. Azisemide and torasemide, long-acting loop diuretics, are more beneficial than the considerably more routinely prescribed short acting furosemide in improving heart failure outcomes. Diuretic dose in the evening appeared to reduce CVEs more than morning dosing. Finally, diuretics are a broad family of medications that continue to play an essential role in the treatment of hypertension and hypervolemic conditions.

Introduction

The use of diuretics is crucial and diverse family of drugs that are often used to treat heart attack, hypertension, and imbalances in electrolytes. The following is a review of the fundamental characteristics of diuretics is discussed, comprises their dose, method of action, adverse reactions, and timing of effects. A discussion some recent randomised trial outcomes follows this. We used PubMed to perform a systematic review that spanned the previous five years for the latter.

Mechanisms of Action

Although there are many different types of diuretics, certain generalisations are still possible. All diuretics, except for vasopressin receptor antagonists and mannitol, begin by blocking salt reabsorption at different sites across the renal tubules. Delivered into the tubular lumen are thiazide diuretics, loop diuretics, carbonic anhydrase inhibitors, and thiazide-like diuretics through the organic acid secretory channel and so reach where they do their work. Aldosterone blockers, on the other hand, go via the bloodstream to their target, the main cortical collecting duct cells.

Salt and bicarbonate reabsorption are inhibited by the carbonic anhydrase inhibitor acetazolamide, and water, which increases the distal distribution of sodium to K+ loss and the distal collecting duct.

Furosemide, torasemide, azosemide, and bumetanide are examples of *loop diuretics* that work where 20–30% happens in the thick ascending limb of the Loop of Henle, where filtered NaCl is reabsorbed. NK-2CL, Na-K transport protein binds loop diuretics, which prevent it from functioning, which lowers the levels of Na, K, and Cl that is reabsorbable and increases the amount of Na that is delivered to the distal tubule. There, it stimulates into the distal tubule, K secretion and increases Na for K exchange. These modifications lessen the kidney's capacity for concentration and osmotic driving power.

Pteridine analogues By shutting off the epithelial Na+ channel in the cortical collecting duct, reabsorption is reduced, which is where potassium sparing diuretics act. Just 3% of filtered Na in the collecting duct is reabsorbed, these medicines produce little diuresis and have little antihypertensive effectiveness as single treatments Instead, they are often used in conjunction with other medicines to treat Deficiency of K+. The combined impact Na+ reabsorption is reduced in both classes, as well as a reduction in Normally occurring H+ and K+ secretion that results from membrane voltage variations.

Mannitol, An osmotic diuretic affects normal tubular water reabsorption by exerting an independent of water level, osmotic impact throughout the length of the renal tubule. Finally, mannitol inhibits the kidney's capacity to concentrate by removing the medullary solute gradient. Thiazides and loop diuretics enhance K+ loss while increasing Na+ supply to the distal nephron.

Increased free water excretion results from inhibiting vasopressin at V2 receptors, vasopressin receptor antagonists decrease reabsorption of free water in the collecting ducts.

Examples, Adverse Reactions, and Pharmacokinetics

The salient pharmacokinetic and clinical characteristics of each subclass of diuretics are summarised in Tables 1 and 2. Changes plasma electrolytes, particularly serum potassium, which may be increased by aldosterone antagonists while being decreased by thiazides and loop diuretics, are the most severe adverse effects. Chlorthalidone, torasemide, and azosemide may have a longer duration of effect contribute to their superior effectiveness in lowering CVEs when compared to its alternatives (see below).[1]

It should be emphasised that the salt and water loss caused by diuretics stimulates Vasopressin, Examples include the sympathetic nervous system and the renin-angiotensin-aldosterone system of hormonal.[2] As a consequence, the dose-BP response curve may be rather flat in hypertensive individuals. However, using chlorthalidone together with spironolactone may help to minimise any side effects.[3]

Thiazides" Are Important in CVE Reduction

Psaty and colleagues demonstrated in 2003, utilising In Low-dose diuretics, including direct and indirect comparisons outperformed the additional primary antihypertensive medication groups in lowering CVEs.[3] In two recent meta-analyses, comparisons are limited and indirect comparisons are minimised to medication class to either placebo or regular therapy.[4] (The word "thiazides" in these research refers to thiazide-type diuretics like chlorthalidone and indapamide, as well as real thiazides like hydrochlorothiazide.)[6]

In one meta-analysis using data, low-dose thiazides showed by far the most evidence of a benefit in lowering CVEs were confined to trials where 70% of participants or more had blood pressure of 139/89 or higher.[5] which included studies in individuals with mostly normal blood pressure, the diuretics thiazide and thiazide-like were shown to suppress CVEs at least as well as other antihypertensive. According to the data in Figure 2, the diuretics thiazide and thiazide-like had a relative risk for stroke outcomes that was P =.014 and P =.047, respectively, both considerably less effective than b-blockers and angiotensin-converting enzyme inhibitors.[6]

In terms of CVE reduction, chlorthalidone outperforms hydrochlorothiazide.

In the US, hydrochlorothiazide is the tenth most often prescribed medication, and it is given more commonly than chlorthalidone by 20 times.[10] Several investigations the impropriety of these individuals has been shown throughout the last five years prescription methods.[11] It has been shown that CTDN is superior to HCTZ in lowering systolic blood pressure by 5 to 6 mm Hg,[12] and as a result of its prolonged duration of action, has a considerably bigger influence on overnight.[13] In a post-hoc examination of data from the multiple risk factor intervention (MRFIT) study, CTDN was linked to a reduced occurrence of left ventricular hypertrophy in comparison to HCTZ.

Table 1. Diuretic indications, contraindications, and adverse effects.

Diuretic	Clinical Uses	Contra Indicator	Adverse Effect
Thiazides	Renal calcium stone, moderate edoema, and nephrogenic diabetic insipidus.	Gout and susceptibility to sulfa substances, liver failure, and kidney failure	orthostatic hypotension. drop in Na, K, Mg, and H levels in the blood. A slight increase in Ca2+. raises triglycerides, cholesterol, LDL, glucose, and uric acid in the blood. Impotence, erectile dysfunction, and lithium storage
loop diuretic	Edematous conditions,	Gout, pregnancy, and	K+, Na+, Mg+, and H+ serum

	such as cirrhosis of the liver, nephrotic syndrome, and hypertension with a glomerular filtration rate ≤ 30 mL/min, as well as congestive heart failure Renal tubular acidosis and hypercalcemia with SIADH NaCl administration	permanent anuria are all symptoms of sulfa hypersensitivity.	levels depletion as well as volume depletion. increased glucose, cholesterol, LDL, triglycerides, and uric acid. ototoxicity, allergic interstitial nephritis, and vomiting
potassium conservation Terridines include triamterene and amiloride.	Teridine derivatives: liedl's syndrome, hypertension with a loss of K+ and/or Mg+	ACEI or ARB usage concurrently, renal failure, liver failure, pregnancy, hyperkalemia, and other conditions (particularly triamterene)	Increase serum K+, Cl-, and H+ concentrations. nephrolithiasis, amiloride or triamterene-related nausea, flatulence, and skin rash Triamterene. reduced libido and gynecomastia in males spironolactone
osmotic agent	cerebral swelling	CHF, volume loss, and permanent anuria	Low volume, K+, and H+, together with heart failure, headache, nausea, vomiting, fever, confusion, and a lethargic condition
Antagonist of arginine vasopressin	usage in the condition of inappropriate antidiuretic hormone in hyponatremia for a brief length of time (euvolemic or hypervolemic).		dry mouth, increased thirst, hypokalemia, and hypernatremia. Everest test results suggest a slight but a statistically significant increase in the risk of trauma.

Thus, based on observational and network analysis, The best estimate for the risk ratio (RR) connecting CTDN to HCTZ in lowering CVEs is 0.79.[18] Recent recommendations in the United Kingdom have advocated For resistant hypertension, CTDN is preferable than HCTZ, hypertension both general practise and therapy for Blacks.[20] Part of the reason for the prescription patterns' immobility is the CTDN pharmaceutical formulations' limited flexibility typically come in a single dosage of 25mg vs 12.5mg, 25mg, and 50 mg for HCTZ, as well as less common combinations of fixed-dose medications. [19]

Table 2. Diuretic half-life, duration of action, and dosage.

Diuretic	Half Life	Duration of action	Dosage in mg
Loop Diuretic			
Furosemide	1.5-2 (Prolonged in ESRD)	4-6	20-48
Torasemide	3-4 (Unchanged in ESRD)	12	5-40
Bumetanide	0.3-1.5 (Unchanged in ESRD)	4-6	0.5-5
Thiazides			
Hydrochlorothiazide	3-10	12-18	12.5-50
Chlorothiazide	15-25	6-12	125-500
Bendroflumethiazide	2.5-5	18	2.5-5
Pteridine Derivative			
Amiloride	17	24	5-10
Triamterene	3	12	50-150
Aldosterone Antagonists			
Spironolactone	10-23	48-72	25-100
Eplerenone	3.4	12	25-100
Vasopressin Receptor			
Tolvaptan			
Lixivaptan	6-8	-	15-60
Conivaptan	7-10	-	50-100
Satavaptan	14-17	-	40-80
Mozavaptan	14-17	-	5-25
	1-8	-	-

Trial Long-Term Monitoring

Patients in ALLHAT were randomly selected to CTDN, lisinopril, or amlodipine are prescribed. Throughout CTDN was better to lisinopril in avoiding CVEs and amlodipine in preventing congestive heart failure throughout the active treatment period (mean 4.9 years) (CHF). A study that lasted 8 to 13 years discovered that CTDN had a consistent advantage Superior to amlodipine for avoiding CHF and lisinopril for decreasing stroke mortality. In both the first 4.9 years and the long-term follow-up, the interaction of race and CTDN vs lisinopril in preventing CVEs was discovered.[19]

According to the Hypertension in the Very Elderly study, patients 80 years of age and older seem to benefit from indapamide as a first-line therapy for high blood pressure.

The advantages of treating hypertension in adults aged 60 and above have been shown in three trials. Recently, the benefit of reducing blood pressure in the extremely old has been discussed. A total of 3845 people without dementia, above the age of 80, and systolic blood pressure off medication of 159 mm Hg were enrolled in the international Hypertension in the Very Elderly Trial. The evaluation of end points was performed in a blinded manner, and all follow-up was completed.[23]





Antagonists of aldosterone

According to the Eplerenone in Mild Patients Hospitalization and Survival Research in Heart Failure Study, eplerenone decreased overall mortality in patients with New York heart failure class II.

Spironolactone reduced overall mortality in New York Heart Class III and IV CHF patients, according to Pitt and colleagues' 1999 research.[20] Aldosterone antagonist eplerenone, has recently been proven to assist people with milder CHF.[24] Class II New York Heart patients in this double-blind study had an ejection fraction of 30% or 30 to 34 percent with a 132 millisecond QRS. In addition, the patients must have hospitalised in the previous 6 months for a cardiovascular cause or have an increased level. Exclusion criteria included having had an over the last 30 days, an acute myocardial infarction (MI), having a a potassium-sparing diuretic is required if you have less than 30 mL/min for glomerular filtration rate, have elevated potassium, or both.[24]

Subjects were assigned to receive eplerenone or a placebo beginning dosage of 24 mg OD increasing to 49 mg OD, or 25 mg every other day for two weeks, then gradually increase to For those with impaired renal function, take 25 mg per day. The allocation was kept secret, An unbiased committee used established criteria to judge the findings, and the follow-up was 99% finished.

Eplerenone Only Reduces Total Mortality After an Acute MI When Used Additional Three to six days for the analysis of the eplerenone post-acute MI heart failure survival trial.

According to a 2003 report[28], Eplerenone had a 0.85 relative risk (95% CI) for total mortality. in individuals with systolic dysfunction after a MI (0.96, 0.75). The effectiveness was shown to be restricted to individuals who received within three to six days after the MI, eplerenone in a more recent review of the same data. In terms of overall mortality, who received eplerenone vs

placebo from 3 to 6 days after MI was 0.69 (0.79, 0.59), P = .004, while the RR for those who received the medication or a placebo from 7 to 14 days after MI was 0.92 (0.80, 1.10), P = .36. P =.003 is a significant statistical value for the interaction effect. The earlier administration of eplerenone was not linked with any significant side effects. The authors postulated that the positive effects of early eplerenone medication could have resulted from the avoidance of postinfarct remodelling and fibrosis linked to elevated Aldosterone levels in the days after MI.[26]

Aldosterone Blockers Lower the Risk of Sudden Cardiac Death

Animal investigations and human trials have shown aldosterone antagonists to minimise ventricular arrhythmias. Wei and colleagues performed Aldosterone antagonists' effectiveness in preventing sudden cardiac death has been the subject of a meta-analysis and thorough study. Aldosterone antagonists, particularly eplerenone, were linked to a lower incidence in a pooled study of two trials of sudden cardiac death including 8294 individuals, with an RR (94% CI) of 0.80 (0.92-0.68), P<.002. Patients assigned in a combined analysis of two investigations, the incidence of ventricular tachycardia was less in those receiving spironolactone, with an RR of 0.29 (0.78-0.11), P<.01. It should be noted that eplerenone has a weaker BP-lowering effect than spironolactone by around two-thirds, therefore combining the two may not be appropriate.[28]

Aldosterone Blockers Lower Proteinuria

In lowering proteinuria, aldosterone antagonists added to normal medication have been shown to be beneficial, according to new results that support earlier research. A placebo or spironolactone was administered to diabetes type 2 patients who were using either an ACE inhibitor or a blocker of the angiotensin receptor following a one-month washout period in a double-blind, crossover randomised experiment.[30] The medication reduced urine protein by a whopping 55%. Similarly, spironolactone reduced urine albumin by 60% in those with type 1 diabetes. 31 Spironolactone lowered proteinuria by 58% to 72% Among those with renal illness who don't have diabetes, whereas eplerenone showed a substantial but less dramatic drop in albuminuria by 23%.[3]

Loop Diuretics

Furosemide vs longer-acting loop diuretics for lowering CVE

Acute coronary syndrome, uncontrolled hyperglycemia, as well as a creatinine level more than 2.5 mg/dL, or acute MI, Exclusions included recent open heart surgery or percutaneous procedures. 98% of the follow-up procedure was finished. After at least two years, the main end's RR (94% CI) objective was 0.54 (0.94-0.31), P =.02, and the RR for the secondary end point was 0.59 (1.01-0.35), P =.049. There were no notable findings changes in hypokalaemia or hypotension between the two groups. Torsemide decreased heart failure readmissions compared to furosemide in a pooled analysis of two trials, RR = 0.41 (0.28-0.61), P<.001.[38] These results are especially significant given the widespread usage of furosemide for heart failure.[35-36]

Evening Loop Diuretic Dosing Improves Blood Pressure Control Compared to Morning Dosing

Because of their lesser antihypertensive effectiveness and a lack of evidence demonstrating a decrease in CVEs, loop diuretics are typically regarded while treating As a third or fourth option among diuretics, hypertension in persons with normal renal function.[41] Loop diuretics, on the other hand, are the most effective diuretics for treating individuals with resistant hypertension who also exhibit significantly in treating renal failure (GFR 30 mL/min) and hypertension, when excess salt and water is a fundamental component of the resistance.[18] A modest dosage of the long-acting drug torsemide (5 mg/d) was recently found to provide significantly When delivered in the evening vs the morning, individuals with grades 1 and 2 hypertension had improved BP control: the drop in ambulatory 24-hour systolic blood pressure was 15 vs 6.3 mm Hg, P.002.[42] With evening dose, the proportion of patients who achieved control increased significantly: 63% versus 24%, P.002.[44]

Diuretics in the Evening (Not Otherwise Specified)

In a single referral centre randomised open label study, nighttime dosage of one or more antihypertensive drugs reduced CVEs compared to morning dose of all medications.[44] This effect was comparable to those of other antihypertensive medications.[43] The possibility of falling and the onset of nocturia were not addressed.

Diuretics with a long half-life and CVE decrease

As previously stated, chlorthalidone and azosemide, are long-acting agents outperform Their short-acting equivalents include furosemide and hydrochlorothiazide. Longacting medicines may provide improved BP control at night by reducing nondipping. The findings on antihypertensive evening doses support this strategy.

Antagonists of the Arginine Vasopressin Receptor

Certain medications have demonstrated to considerably enhance maintaining electrolyte equilibrium during diuresis. Both oral tolvaptan and intravenous conivaptan kept blood salt levels in CHF patients stable despite increased diuresis.[46-48] When used with furosemide and spironolactone, satavaptan reduces ascites.[49,50]

Conclusion

Diuretics are a varied family of medications that are still used to treat hypertension and hypervolemic conditions.

Reference

1. Burnier M, Brunner HR. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J. 1992; 13(suppl G):28-33.
2. Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94(4):1361-1366.
3. Raheja P, Price A, Wang Z, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60(2):319-325.
4. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-2544.
5. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;(3):CD001841.
6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiologic studies. BMJ. 2009;338:b1665.
7. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689-694.
8. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012; 59(6):1110-1117.
9. IMS. Top 20 U.S. Pharmaceutical Products by Dispensed Prescriptions 2011. Danbury, CT: IMS.
10. Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens. 2010;12(12):927-934.
11. Kuehlein T, Lauz G, Gutscher A, Goetz K, Szecseny J. Diuretics for hypertension: an inconsistency in primary care prescribing behavior. Curr Med Res Opin. 2011;27(3):497-502.
12. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352-358.
13. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide versus chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12):1229.e1-1229.e10.
14. Ernst ME, Neaton JD, Grimm RH Jr, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011;58(6):1001-1007.
15. Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension: a populationbased cohort study. Ann Intern Med. 2013;158(6):447-455.
16. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based lowdose diuretic therapies. JAMA. 2004;292(1):43-44.
17. Elliott WJ, Childers WK, Meyer PM. Poster PO-91: outcomes with different diuretics in clinical trials in hypertension: results of network and Bayesian meta-analyses. J Clin Hypertension. 2012;14(suppl 1).
18. Calhoun DA, Jones D, Textor S, et al; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-e526.
19. Flack JM, Sica DA, Bakris G, et al. Society on Hypertension in Blacks Consensus Statement Management of High Blood Pressure in Blacks: an Update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010;56: 78-800.
20. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B; Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891. doi: 10. 1136/bmj.d4891.
21. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011;306(23):2588-2593.
22. Cushman WC, Davis BR, Pressel SL, et al. ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012;14(1):20-31.
23. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.
24. Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
25. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.

26. Edelmann F, Wachter R, Schmidt AG, et al; Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013; 309(8):781-791.
27. Adamopoulos C, Ahmed A, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart fail. 2009;11(11):1099-1105.
28. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321.
29. Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin Cardiol. 2010;33(9):572-577.
30. Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008;56(4):714-719.
31. Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012;29(8):e184-e190.
32. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of reninangiotensin- aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31(1):59-67.
33. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52(3):486-493.
34. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockadewith eplerenone in non-diabetic chronic kidney disease. Arandomized cross-over study. PLoS One. 2011;6(11):e26904.
35. Parthasarathy HK, Me´nard J,WhiteWB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980-990.
36. Hisatake S, Nanjo S, Fujimoto S, et al. Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using (123)Imetaiodobenzylguanidine scintigraphy. Eur J Heart Fail. 2011; 13(8):892-898.
37. Masuyama T, Tsujino T, Origasa H, et al. Superiority of longacting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012;76(4):833-842.
38. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol. 2012;8(5): 707-728.
39. Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, O'Connor CM. Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010;105(12): 1794-1797.
40. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011; 364(9):797-805.
41. Hermida RC, Ayala DE, Mojo´n A, et al. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int. 2008;25(6):950-970.
42. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639-643.
43. Sanjay S,AnnigeriRA, SeshadriR, RaoBS, PrakashKC,ManiMK. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease. Nephrology (Carlton). 2008;13(3):247-250.
44. Hermida RC, Ayala DE, Mojo´n A, Ferna´ndez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010;27(8):1629-1651.
45. Hermida RC, Ayala DE, Mojo´n A, Ferna´ndez JR Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol Int. 2013;30(1-2):315-327.
46. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A; Tolvaptan Investigators. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther. 2011;25(suppl 1):S57-S65.
47. Udelson JE, Bilsker M, Hauptman PJ, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17(12):973-981.
48. Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail. 2011;17(12):982-989.
49. Wong F, Gines P,Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53(2):283-290.
50. Gine`s P, Wong F, Watson H, et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia—a randomized, double-blind, placebocontrolled study. Aliment Pharmacol Ther. 2010;31(8):834-845.